Adamis Pharmaceuticals Announces Appointment of New Members to Its Board of Directors
26 Agosto 2019 - 3:05PM
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced
the appointment of Howard C. Birndorf and Roshawn Blunt to its
Board of Directors.
Dr. Dennis J. Carlo, President and CEO of Adamis, stated, “We
are very excited to bring on these two new members with such strong
credentials to Adamis’ Board. They bring tremendous
leadership, creativity, success, reimbursement, market access,
compliance, and healthcare innovation to the company.
Together, they provide us with years of experience and expertise
that will help enable us to move into the next stages of corporate
development. Their proven track record, knowledge and
relationships in the pharmaceuticals area will be an asset to the
company as we continue our transition from a development company
into a company with several sources of revenues.”
The new board additions include:
Howard C. Birndorf: Mr. Birndorf is a
biotechnology entrepreneur and one of the founders of the biotech
industry in San Diego, California. In 1978, Birndorf co-founded San
Diego’s first biotech, the monoclonal antibody company
Hybritech. The company was subsequently bought by Eli Lilly
and Company in 1986, and Mr. Birndorf went on to found or co-found
a number of other successful companies including Gen-Probe, IDEC
Pharmaceuticals (which merged with Biogen to form Biogen-Idec), and
Ligand Pharmaceuticals. Birndorf was also involved in the
formation of Gensia (Sicor) and was a director of Neurocrine
Biosciences. He was the founder and co-chair of the Coalition
for 21st Century Medicine and was co-founder, Chairman and CEO of
Nanogen, Inc. Birndorf received his B.A. in Biology from
Oakland University, an M.S. in Biochemistry from Wayne State
University, and has received honorary Doctor of Science degrees
from Oakland University and Wayne State University.
Roshawn Blunt: Ms. Blunt has more than 20
years of experience in the biopharmaceutical and medical device
industries. Currently, Ms. Blunt founded and is managing
director of 1798 Consultants, which is a national healthcare
consulting firm focused on educating and developing strategies for
clients to address healthcare compliance, reimbursement, health
policy and patient access issues. She began her
pharmaceutical career at The Boston Consulting Group, working
primarily on cases in the healthcare industry. She has held a
variety of strategic reimbursement and commercialization positions
of increasing importance at Amgen, Inc. including involvement in
the marketing of Aranesp and acting as global government affairs
director in the company’s Washington DC office. Ms. Blunt was also
the first global director of health economics and reimbursement for
Biosense Webster, a Johnson & Johnson company. Prior to
starting 1798 Consultants, she was vice president of strategy,
planning, and communication at Long Beach Memorial Center and
Miller Children’s Hospital. Ms. Blunt graduated from
Princeton University, where she received her A.B. from the Woodrow
Wilson School of International and Public Policy. She earned
her M.B.A. from Kellogg School of Management at Northwestern
University.
These two new independent board members have replaced Robert B.
Rothermel, who has resigned from the Board for personal
reasons. Additional information concerning his resignation is
contained in a report on Report on Form 8-K that the Company will
file with the Securities and Exchange Commission.
Richard C. Williams, Chairman, added, “The Company would like to
thank Robert B. Rothermel for his contributions in helping grow the
company and wish him the very best in his future endeavors.”
About Adamis Pharmaceuticals Corporation
Adamis Pharmaceuticals Corporation is a specialty
biopharmaceutical company primarily focused on developing and
commercializing products in various therapeutic areas, including
respiratory disease, allergy and opioid overdose. The
company’s SYMJEPI (epinephrine) Injection 0.3mg and SYMJEPI
(epinephrine) Injection 0.15mg products were approved by the FDA
for use in the emergency treatment of acute allergic reactions,
including anaphylaxis. In July, Sandoz, a division of
Novartis Group, announced it had fully launched both in the
U.S. Please refer to www.SYMJEPI.com for additional product
information. Adamis is developing additional products,
including a naloxone injection product candidate, ZIMHI, for the
treatment of opioid overdose, and a metered dose inhaler and dry
powder inhaler product candidates for the treatment of asthma and
COPD. The company’s subsidiary, U.S. Compounding, Inc.,
compounds sterile prescription drugs, and certain nonsterile drugs
for patients, animals, hospitals, clinics and surgery centers
throughout most of the United States.
Contact:
Mark FlatherSenior Director, Investor Relations &Corporate
CommunicationsAdamis Pharmaceuticals Corporation(858)
412-7951mflather@adamispharma.com
Adamis Pharmaceuticals (NASDAQ:ADMP)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Adamis Pharmaceuticals (NASDAQ:ADMP)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024